What is Silence Therapeutics Plc's earnings per share (EPS)?

Silence Therapeutics Plc (SLN) reported diluted earnings per share of $-0.63 for fiscal year 2025. This represents a -90.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Silence Therapeutics Plc Financials

SLN

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Silence Therapeutics Plc (SLN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SLN FY2025 2026-05-07

A development-stage R&D model dominates, with cash burn driven far more by research spending than by recurring revenue.

The swing from $43.3M of revenue in FY2024 to just $559K in FY2025 barely changed the cost base: R&D spend held near $67.8M and operating cash burn remained -$62.3M. That makes reported revenue look episodic rather than load-bearing, so FY2024’s $142.1M financing inflow functioned more like a temporary fuel tank than evidence the business had started funding itself.

FY2025 still shows paper liquidity: current assets of $118.7M sit against just $13.6M of current liabilities. But cash fell to $11.3M, below those liabilities, so near-term flexibility depends on other liquid current assets rather than cash alone.

Leverage worsened mainly because equity was consumed by losses, not because liabilities expanded; total liabilities stayed near $69.1M while equity fell from $134.0M to $62.3M. With capex at just $55K, this is an asset-light but funding-intensive business where the drain comes from ongoing R&D, not heavy infrastructure.

Financial Health Signals

Financial health score pending refresh

We are recalculating Silence Therapeutics Plc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-3.27

Silence Therapeutics Plc scores -3.27, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($465.7M) relative to total liabilities ($69.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/8

Silence Therapeutics Plc passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.70x

For every $1 of reported earnings, Silence Therapeutics Plc generates $0.70 in operating cash flow (-$62.3M OCF vs -$88.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$559K

YoY-98.7%

Silence Therapeutics Plc generated $559K in revenue in fiscal year 2025. This represents a decrease of 98.7% from the prior year.

EBITDA

-$90.8M

YoY-44.1%

Silence Therapeutics Plc's EBITDA was -$90.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 44.1% from the prior year.

Net Income

-$88.6M

YoY-95.6%

Silence Therapeutics Plc reported -$88.6M in net income in fiscal year 2025. This represents a decrease of 95.6% from the prior year.

EPS (Diluted)

$-0.63

YoY-90.9%

Silence Therapeutics Plc earned $-0.63 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 90.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$62.3M

YoY+8.1%

Silence Therapeutics Plc generated -$62.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 8.1% from the prior year.

Cash & Debt

$11.3M

YoY-90.7%

Silence Therapeutics Plc held $11.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

142M

YoY+0.0%

Silence Therapeutics Plc had 142M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

61.5%

YoY-11.2pp

Silence Therapeutics Plc's gross margin was 61.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.2 percentage points from the prior year.

Operating Margin

-16292.8%

YoY-16146.5pp

Silence Therapeutics Plc's operating margin was -16292.8% in fiscal year 2025, reflecting core business profitability. This is down 16146.5 percentage points from the prior year.

Net Margin

-15851.5%

YoY-15746.8pp

Silence Therapeutics Plc's net profit margin was -15851.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 15746.8 percentage points from the prior year.

Return on Equity

-142.2%

YoY-108.4pp

Silence Therapeutics Plc's ROE was -142.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 108.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$67.8M

YoY-0.2%

Silence Therapeutics Plc invested $67.8M in research and development in fiscal year 2025. This represents a decrease of 0.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$55K

YoY-73.9%

Silence Therapeutics Plc invested $55K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 73.9% from the prior year.

SLN Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	$559K-98.7%	$43.3M+36.7%	$31.6M+46.1%	$21.7M
Cost of Revenue	$215K-98.2%	$11.8M-8.2%	$12.9M-4.4%	$13.5M
Gross Profit	$344K-98.9%	$31.4M+67.5%	$18.8M+129.2%	$8.2M
R&D Expenses	$67.8M-0.2%	$67.9M+19.2%	$56.9M+30.7%	$43.5M
SG&A Expenses	$22.3M-16.9%	$26.9M+2.5%	$26.2M+2.1%	$25.7M
Operating Income	-$91.1M-43.8%	-$63.3M+1.7%	-$64.4M-5.5%	-$61.0M
Interest Expense	N/A	N/A	N/A	N/A
Income Tax	$11K-98.7%	$845K-11.6%	$956K+39.0%	$688K
Net Income	-$88.6M-95.6%	-$45.3M+16.4%	-$54.2M-7.7%	-$50.3M
EPS (Diluted)	$-0.63-90.9%	$-0.33+32.7%	$-0.49+5.8%	$-0.52

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$422K+1141.2%	$34K-78.6%	$159K-29.0%	$224K+57.7%	$142K-99.4%	$25.3M+1589.3%	$1.5M+98.1%	$756K
Cost of Revenue	$11K-8.3%	$12K-81.3%	$64K-24.7%	$85K+57.4%	$54K-97.4%	$2.0M-44.0%	$3.6M+9.2%	$3.3M
Gross Profit	$411K+1768.2%	$22K-76.8%	$95K-31.7%	$139K+58.0%	$88K-99.6%	$23.3M+1186.7%	-$2.1M+16.9%	-$2.6M
R&D Expenses	$9.1M+4.3%	$8.7M-57.4%	$20.5M+16.4%	$17.6M-15.2%	$20.8M-5.7%	$22.1M+9.5%	$20.2M+46.1%	$13.8M
SG&A Expenses	$7.0M+88.2%	$3.7M-35.6%	$5.8M+12.9%	$5.1M-33.2%	$7.7M+38.6%	$5.5M-28.0%	$7.7M+9.8%	$7.0M
Operating Income	-$15.7M-26.3%	-$12.5M+52.5%	-$26.2M-9.5%	-$24.0M+15.6%	-$28.4M-552.6%	-$4.4M+85.5%	-$30.0M-28.3%	-$23.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0-100.0%	$1K-90.0%	$10K	$0-100.0%	$324K+561.2%	$49K-78.5%	$228K
Net Income	-$15.0M-27.1%	-$11.8M+43.8%	-$21.0M+23.4%	-$27.4M+4.1%	-$28.5M-331.9%	$12.3M+134.6%	-$35.5M-79.9%	-$19.8M
EPS (Diluted)	$-0.11	N/A	$-0.15+21.1%	$-0.19+5.0%	$-0.20	N/A	$-0.25-78.6%	$-0.14

SLN Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$131.4M-35.1%	$202.6M+69.6%	$119.4M	N/A
Current Assets	$118.7M-36.7%	$187.4M+81.6%	$103.2M	N/A
Cash & Equivalents	$11.3M-90.7%	$121.3M+76.4%	$68.8M	N/A
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$972K+235.2%	$290K	N/A
Goodwill	$10.6M+13.1%	$9.4M-5.9%	$10.0M+3.1%	$9.7M
Total Liabilities	$69.1M+0.8%	$68.6M-29.6%	$97.5M	N/A
Current Liabilities	$13.6M-19.1%	$16.8M-24.7%	$22.3M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$62.3M-53.5%	$134.0M+509.4%	$22.0M-19.2%	$27.2M
Retained Earnings	-$562.6M-18.7%	-$474.0M-9.8%	-$431.9M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$115.1M-12.4%	$131.4M-10.5%	$146.8M-11.2%	$165.2M-10.8%	$185.3M-8.6%	$202.6M	N/A	N/A
Current Assets	$102.9M-13.3%	$118.7M-11.2%	$133.6M-10.0%	$148.6M-12.5%	$169.8M-9.4%	$187.4M	N/A	N/A
Cash & Equivalents	$5.7M-49.8%	$11.3M-86.3%	$82.0M+96.5%	$41.7M-35.7%	$64.9M-46.5%	$121.3M	N/A	N/A
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0-100.0%	$28K-67.1%	$85K+107.3%	$41K-95.8%	$972K	N/A	N/A
Goodwill	$10.4M-2.5%	$10.6M+0.1%	$10.6M0.0%	$10.6M0.0%	$10.6M+13.1%	$9.4M0.0%	$9.4M	N/A
Total Liabilities	$65.7M-4.9%	$69.1M-4.9%	$72.7M+2.3%	$71.1M-2.0%	$72.6M+5.7%	$68.6M	N/A	N/A
Current Liabilities	$10.5M-23.2%	$13.6M-21.7%	$17.4M+17.7%	$14.8M-23.3%	$19.3M+14.5%	$16.8M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$49.4M-20.7%	$62.3M-15.9%	$74.1M-21.3%	$94.2M-16.5%	$112.7M-15.9%	$134.0M+5.8%	$126.7M-11.1%	$142.5M
Retained Earnings	-$577.5M-2.7%	-$562.6M-2.1%	-$550.8M-4.0%	-$529.8M-5.4%	-$502.5M-6.0%	-$474.0M	N/A	N/A

SLN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$62.3M+7.9%	-$67.6M-36.8%	-$49.5M+13.3%	-$57.0M
Capital Expenditures	$55K-73.9%	$211K+276.8%	$56K-67.6%	$173K
Free Cash Flow	-$62.3M+8.1%	-$67.9M-37.0%	-$49.5M+13.5%	-$57.2M
Investing Cash Flow	-$48.0M-118.5%	-$22.0M-213.8%	$19.3M+194.1%	-$20.5M
Financing Cash Flow	$15K-100.0%	$142.1M+344.9%	$31.9M-39.3%	$52.6M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$15.6M+9.7%	-$17.3M-58.7%	-$10.9M+50.0%	-$21.8M-77.0%	-$12.3M+55.2%	-$27.5M-7.3%	-$25.6M-373.4%	-$5.4M
Capital Expenditures	$0	$0-100.0%	$3K-93.8%	$48K+1100.0%	$4K-93.5%	$62K-3.1%	$64K-24.7%	$85K
Free Cash Flow	-$15.6M+9.7%	-$17.3M-58.7%	-$10.9M+50.1%	-$21.8M-77.3%	-$12.3M+55.3%	-$27.5M-7.3%	-$25.7M-367.3%	-$5.5M
Investing Cash Flow	$10.0M+118.7%	-$53.3M-204.0%	$51.3M+3383.5%	-$1.6M+96.5%	-$44.4M-167.1%	$66.1M+273.4%	-$38.1M-88597.7%	-$43K
Financing Cash Flow	$0	$0	$0-100.0%	$1K-92.9%	$14K+114.3%	-$98K-101.2%	$8.0M+568.2%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SLN Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	61.5%-11.2pp	72.7%+13.4pp	59.3%+21.5pp	37.8%
Operating Margin	-16292.8%-16146.5pp	-146.4%+57.1pp	-203.5%+78.4pp	-281.9%
Net Margin	-15851.5%-15746.8pp	-104.7%+66.6pp	-171.4%+61.1pp	-232.4%
Return on Equity	-142.2%-108.4pp	-33.8%+212.8pp	-246.6%-61.7pp	-184.9%
Return on Assets	-67.4%-45.1pp	-22.4%+23.0pp	-45.4%	N/A
Current Ratio	8.72-2.4	11.14+6.5	4.62	N/A
Debt-to-Equity	1.11+0.6	0.51-3.9	4.43	N/A
FCF Margin	-11149.6%-10992.7pp	-156.8%-0.4pp	-156.5%+107.7pp	-264.2%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	97.4%+32.7pp	64.7%+5.0pp	59.8%-2.3pp	62.1%+0.1pp	62.0%-30.0pp	92.0%+234.9pp	-142.9%+198.0pp	-340.9%
Operating Margin	-3729.2%+32920.8pp	-36650.0%-20144.3pp	-16505.7%-5807.9pp	-10697.8%+9308.6pp	-20006.3%-19989.1pp	-17.2%+1985.3pp	-2002.5%+1091.2pp	-3093.7%
Net Margin	-3544.3%+31067.4pp	-34611.8%-21430.6pp	-13181.1%-969.5pp	-12211.6%+7879.9pp	-20091.5%-20140.2pp	48.6%+2421.4pp	-2372.8%+240.3pp	-2613.1%
Return on Equity	-30.3%-11.4pp	-18.9%+9.4pp	-28.3%+0.8pp	-29.0%-3.7pp	-25.3%-34.5pp	9.2%+37.2pp	-28.1%-14.2pp	-13.9%
Return on Assets	-13.0%-4.0pp	-8.9%+5.3pp	-14.3%+2.3pp	-16.6%-1.2pp	-15.4%-21.5pp	6.1%	N/A	N/A
Current Ratio	9.83+1.1	8.72+1.0	7.69-2.4	10.06+1.2	8.81-2.3	11.14	N/A	N/A
Debt-to-Equity	1.33+0.2	1.11+0.1	0.98+0.2	0.75+0.1	0.64+0.1	0.51	N/A	N/A
FCF Margin	-3697.4%+47146.7pp	-50844.1%-43992.6pp	-6851.6%+2894.9pp	-9746.4%-1075.3pp	-8671.1%-8562.3pp	-108.8%+1604.8pp	-1713.7%-987.0pp	-726.7%

Similar Companies

AC Immune ACIU

$264.6M

Proqr Therapeuti PRQR

$248.4M

Vor Biopharma Inc. VOR

$1.1B

Sagimet Biosciences Inc. SGMT

$453.9M

Puma Biotechnology Inc PBYI

$402.1M

Frequently Asked Questions

What is Silence Therapeutics Plc's annual revenue?

Silence Therapeutics Plc (SLN) reported $559K in total revenue for fiscal year 2025. This represents a -98.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Silence Therapeutics Plc's revenue growing?

Silence Therapeutics Plc (SLN) revenue declined by 98.7% year-over-year, from $43.3M to $559K in fiscal year 2025.

Is Silence Therapeutics Plc profitable?

No, Silence Therapeutics Plc (SLN) reported a net income of -$88.6M in fiscal year 2025, with a net profit margin of -15851.5%.

What is Silence Therapeutics Plc's EBITDA?

Silence Therapeutics Plc (SLN) had EBITDA of -$90.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Silence Therapeutics Plc's gross margin?

Silence Therapeutics Plc (SLN) had a gross margin of 61.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Silence Therapeutics Plc's operating margin?

Silence Therapeutics Plc (SLN) had an operating margin of -16292.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Silence Therapeutics Plc's net profit margin?

Silence Therapeutics Plc (SLN) had a net profit margin of -15851.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Silence Therapeutics Plc's return on equity (ROE)?

Silence Therapeutics Plc (SLN) has a return on equity of -142.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Silence Therapeutics Plc's free cash flow?

Silence Therapeutics Plc (SLN) generated -$62.3M in free cash flow during fiscal year 2025. This represents a 8.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Silence Therapeutics Plc's operating cash flow?

Silence Therapeutics Plc (SLN) generated -$62.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Silence Therapeutics Plc's total assets?

Silence Therapeutics Plc (SLN) had $131.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Silence Therapeutics Plc's capital expenditures?

Silence Therapeutics Plc (SLN) invested $55K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Silence Therapeutics Plc spend on research and development?

Silence Therapeutics Plc (SLN) invested $67.8M in research and development during fiscal year 2025.

How many shares does Silence Therapeutics Plc have outstanding?

Silence Therapeutics Plc (SLN) had 142M shares outstanding as of fiscal year 2025.

What is Silence Therapeutics Plc's current ratio?

Silence Therapeutics Plc (SLN) had a current ratio of 8.72 as of fiscal year 2025, which is generally considered healthy.

What is Silence Therapeutics Plc's debt-to-equity ratio?

Silence Therapeutics Plc (SLN) had a debt-to-equity ratio of 1.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Silence Therapeutics Plc's return on assets (ROA)?

Silence Therapeutics Plc (SLN) had a return on assets of -67.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Silence Therapeutics Plc's cash runway?

Based on fiscal year 2025 data, Silence Therapeutics Plc (SLN) had $11.3M in cash against an annual operating cash burn of $62.3M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Silence Therapeutics Plc's Altman Z-Score?

Silence Therapeutics Plc (SLN) has an Altman Z-Score of -3.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Silence Therapeutics Plc's Piotroski F-Score?

Silence Therapeutics Plc (SLN) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Silence Therapeutics Plc's earnings high quality?

Silence Therapeutics Plc (SLN) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.